Live Webinar
GXC 2025 Online Virtual Conference - Mental Health Without Borders
The New Frontier of GLP-1Ra Medications in Addiction Treatment: What we know, what we don’t and what we’re doing.
|
The New Frontier of GLP-1Ra Medications in Addiction Treatment: What we know, what we don’t and what we’re doing.
1.0 CE Hours
Intermediate
$99
Pricing
References
References
- Klausen MK, Jensen ME, Møller M, Le Dous N, Jensen AØ, Zeeman VA, Johannsen CF, Lee A, Thomsen GK, Macoveanu J, Fisher PM, Gillum MP, Jørgensen NR, Bergmann ML, Enghusen Poulsen H, Becker U, Holst JJ, Benveniste H, Volkow ND, Vollstädt-Klein S, Miskowiak KW, Ekstrøm CT, Knudsen GM, Vilsbøll T, Fink-Jensen A. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight. 2022 Oct 10;7(19):e159863. doi: 10.1172/jci.insight.159863. PMID: 36066977; PMCID: PMC9675448.
- Hendershot CS, Bremmer MP, Paladino MB, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025;82(4):395–405.
- Egecioglu E, Engel JA, Jerlhag E. The glucagon-like peptide 1 analogue, exendin-4, attenuates the rewarding properties of psychostimulant drugs in mice. PLoS One. 2013 Jul 16;8(7):e69010. doi: 10.1371/journal.pone.0069010. PMID: 23874851; PMCID: PMC3712951.
- Fortin SM, Roitman MF. Central GLP-1 receptor activation modulates cocaine-evoked phasic dopamine signaling in the nucleus accumbens core. Physiol Behav. 2017 Jul 1;176:17-25. doi: 10.1016/j.physbeh.2017.03.019. Epub 2017 Mar 16. PMID: 28315693; PMCID: PMC5763906.